Insider Trading disclosures for enGene Holdings Inc

The latest disclosure was made by Raj Som Pruthi in enGene Holdings Inc where a trade of 280,000 Stock Option (Right to Buy) done was reported to US exchanges on Jan. 29, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Raj Som Pruthi	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	29 Jan 2025	280,000	280,000	-		-	Stock Option (Right to Buy)
Ryan Daws	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	29 Jan 2025	280,000	280,000	-		-	Stock Option (Right to Buy)
Ronald H.W. Cooper	Director, CEO & President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	29 Jan 2025	850,000	850,000	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	29 Jan 2025	250,000	250,000	-		-	Stock Option (Right to Buy)
Alexander Julian Nichols	Chief Strategy & Ops. Ofc	Grant, award, or other acquisition of securities at price $ 0.00 per share.	29 Jan 2025	250,000	250,000	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Oct 2024	100,000	100,000	-		-	Stock Option (Right to Buy)
Joan Connolly	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Oct 2024	210,000	210,000	-		-	Stock Option (Right to Buy)
Ronald H.W. Cooper	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 5.70 per share.	27 Sep 2024	10,000	10,000	-	5.7	57,000	Common Shares
Raj Som Pruthi	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	24 Jul 2024	110,000	110,000	-		-	Stock Option (Right to Buy)
Ronald H.W. Cooper	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jul 2024	1,250,000	1,250,000	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2024	20,000	20,000	-		-	Stock Option (Right to Buy)
Wouter Joustra	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2024	40,000	40,000	-		-	Stock Option (Right to Buy)
Jasper Bos	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2024	20,000	20,000	-		-	Stock Option (Right to Buy)
Paul J. Hastings	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2024	40,000	40,000	-		-	Stock Option (Right to Buy)
Lota S. Zoth	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2024	20,000	20,000	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	28 May 2024	120	0	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.89 per share.	28 May 2024	120	24,675	-	0.9	107	Common Shares
Lota S. Zoth	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Mar 2024	40,000	40,000	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Mar 2024	52,940	0	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.89 per share.	18 Mar 2024	52,940	102,873	-	0.9	47,117	Common Shares
Richard P. Bryce	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Nov 2023	153,000	153,000	-		-	Stock Option (Right to Buy)
Ryan Daws	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Nov 2023	232,000	232,000	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	52,940	52,940	-		-	Stock Option (Right to Buy)
Jason D. Hanson	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	524,544	524,544	-		-	Stock Option (Right to Buy)
Jason D. Hanson	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	512,826	512,826	-		-	Stock Option (Right to Buy)
Jason D. Hanson	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	10,906	10,906	-		-	Stock Option (Right to Buy)
Jason D. Hanson	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	30,939	30,939	-		-	Stock Option (Right to Buy)
Jason D. Hanson	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	137,051	137,051	-		-	Stock Option (Right to Buy)
James Crowley Sullivan	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	88,901	88,901	-		-	Stock Option (Right to Buy)
James Crowley Sullivan	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	118,509	118,509	-		-	Stock Option (Right to Buy)
Alexander Julian Nichols	Pres. & Chief Operating Ofc.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	177,935	177,935	-		-	Stock Option (Right to Buy)
Alexander Julian Nichols	Pres. & Chief Operating Ofc.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	101,924	101,924	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	1,266	1,266	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	22,860	22,860	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	28,876	28,876	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	49,933	49,933	-		-	Common Shares
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	185,222	185,222	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	2,255	2,255	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	155,472	155,472	-		-	Stock Option (Right to Buy)
Anthony Tzeyew Cheung	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	36,618	36,618	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	4,123	4,123	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	12,032	12,032	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	14,205	14,205	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	12,001	12,001	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	11,189	11,189	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	120	120	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	24,555	24,555	-		-	Common Shares
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	9,023	9,023	-		-	Stock Option (Right to Buy)
Richard M. Glickman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Oct 2023	3,188	3,188	-		-	Stock Option (Right to Buy)

Showing 1 to 49 of 49 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

73.75% Fall from 52W High

Insider Trading disclosures for enGene Holdings Inc

The latest disclosure was made by Raj Som Pruthi in enGene Holdings Inc where a trade of 280,000 Stock Option (Right to Buy) done was reported to US exchanges on Jan. 29, 2025.

Screeners based on Insider Trading and SAST parameters